Cadonilimab: all 158 studies that test it
Page 1 of 2. Open to participants first (105), then studies with results posted, then the rest; newest registration first within each.
- FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)RecruitingNCT07815834Phase 3
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Phase 3
- A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction CancerRecruitingNCT07631000Phase 2
- A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsNot yet recruitingNCT07619001Phase 1
- AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)RecruitingNCT07544784Phase 2
- Cadonilimab Combined With RT in LACC Patients Ineligible for CCRTNot yet recruitingNCT07450963Phase 2
- A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07449780Phase 3
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingNCT07446257Early Phase 1
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingNCT07412613Phase 3
- Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)RecruitingNCT07263919Phase 2
- Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaNot yet recruitingNCT07243951Phase 2
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Phase 2
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Phase 3
- A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical CancerRecruitingNCT06998394Phase 2
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
- Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNot yet recruitingNCT06946836Phase 2
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingNCT06789848Phase 2
- Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCRecruitingNCT06769971Phase 2
- Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06715501Not applicable
- Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
- IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingNCT06654011Phase 2
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCRecruitingNCT06617416Phase 3
- Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingNCT06577961Phase 1/2
- Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal CancerRecruitingNCT06566755Phase 3
- An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecruitingNCT06560112Phase 2
- Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNCT06551207Not applicable
- Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerNot yet recruitingNCT06542549Phase 3
- Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLCRecruitingNCT06532591Phase 2
- Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingNCT06532539Phase 2
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingNCT06519591Phase 2
- RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Phase 2
- AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
- A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed ImmunotherapyRecruitingNCT06467500Phase 2
- Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingNCT06455254Phase 2
- Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical CancerRecruitingNCT06455046Phase 2
- A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System TumorsNot yet recruitingNCT06427057Phase 2
- Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
- Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLCRecruitingNCT06424821Phase 2
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
- Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural MesotheliomaNot yet recruitingNCT06416930Phase 2
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
- SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)RecruitingNCT06401005Phase 2
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
- Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast CancerRecruitingNCT06367088Phase 2
- A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue SarcomaRecruitingNCT06367075Phase 2
- Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric CancerNot yet recruitingNCT06349967Phase 2
- To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06341660Phase 2
- A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06341335Phase 3
- A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung CancerRecruitingNCT06331650Phase 2
- Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy FailureNot yet recruitingNCT06327698Phase 2
- Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialNot yet recruitingNCT06310473Phase 2
- Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical CancerRecruitingNCT06289751Phase 2
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingNCT06280105Phase 2
- Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
- A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical CancerRecruitingNCT06251388Phase 2
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
- Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
- Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT06215651Phase 2
- Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving SurgeryRecruitingNCT06209294Phase 2
- Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingNCT06202313Phase 2
- A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06196775Phase 2
- AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingNCT06196697Phase 2
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Phase 2
- A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06178601Phase 2
- Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNCT06168786Phase 2
- Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPCNot yet recruitingNCT06153368Phase 2
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
- A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT06074484Phase 2
- Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial CancerNot yet recruitingNCT06066216Phase 2
- Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT06040177Phase 1/2
- Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder CancerRecruitingNCT06009848Phase 2
- A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Phase 3
- Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal CancerRecruitingNCT05980689Phase 2
- Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric CancerNot yet recruitingNCT05974059Phase 2
- To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Not yet recruitingNCT05948449Phase 2
- A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.RecruitingNCT05944224Phase 1/2
- Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaRecruitingNCT05930665Phase 2
- Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard TreatmentRecruitingNCT05926700Phase 2
- Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid TumorsNot yet recruitingNCT05915481Phase 1/2
- Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLCRecruitingNCT05901584Phase 2
- Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT05898256Phase 1/2
- Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT05896787Phase 2
- TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II StudyRecruitingNCT05882370Phase 2
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
- Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
- Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05833971Phase 2
- Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint InhibitorsNot yet recruitingNCT05824494Phase 2
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingNCT05817214Phase 2
- XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal CancerRecruitingNCT05815303Phase 2
- Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal CancerRecruitingNCT05815290Phase 2
- Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNot yet recruitingNCT05812534Phase 2
- Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）Not yet recruitingNCT05794750Phase 2
- Cadonilimab (AK104) in the Treatment of Nasopharyngeal CarcinomaRecruitingNCT05790200Phase 2
- Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung CancerNot yet recruitingNCT05784974Phase 2
- SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCCNot yet recruitingNCT05732662Phase 2
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
- AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05594914Phase 2